PH31327A - Method for inhibiting vasomotor symptoms and attending psychological disturbances surrounding post-menopausal syndrome. - Google Patents

Method for inhibiting vasomotor symptoms and attending psychological disturbances surrounding post-menopausal syndrome.

Info

Publication number
PH31327A
PH31327A PH49586A PH49586A PH31327A PH 31327 A PH31327 A PH 31327A PH 49586 A PH49586 A PH 49586A PH 49586 A PH49586 A PH 49586A PH 31327 A PH31327 A PH 31327A
Authority
PH
Philippines
Prior art keywords
attending
vasomotor symptoms
menopausal syndrome
psychological disturbances
surrounding post
Prior art date
Application number
PH49586A
Other languages
English (en)
Inventor
George J Cullinan
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PH31327A publication Critical patent/PH31327A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PH49586A 1993-12-21 1994-12-19 Method for inhibiting vasomotor symptoms and attending psychological disturbances surrounding post-menopausal syndrome. PH31327A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/173,502 US5534526A (en) 1993-12-21 1993-12-21 Methods for inhibiting vasomotor symptoms and attending psychological disturbances surrounding post-menopausal syndrome

Publications (1)

Publication Number Publication Date
PH31327A true PH31327A (en) 1998-07-06

Family

ID=22632322

Family Applications (1)

Application Number Title Priority Date Filing Date
PH49586A PH31327A (en) 1993-12-21 1994-12-19 Method for inhibiting vasomotor symptoms and attending psychological disturbances surrounding post-menopausal syndrome.

Country Status (15)

Country Link
US (1) US5534526A (no)
EP (1) EP0659415A3 (no)
JP (1) JPH07196500A (no)
KR (1) KR950016730A (no)
CN (1) CN1108093A (no)
AU (1) AU691844B2 (no)
CA (1) CA2138499A1 (no)
CZ (1) CZ320994A3 (no)
HU (1) HUT71478A (no)
IL (1) IL112038A0 (no)
NO (1) NO944934L (no)
NZ (1) NZ270168A (no)
PH (1) PH31327A (no)
RU (1) RU94045278A (no)
ZA (1) ZA9410093B (no)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6417198B1 (en) 1993-12-21 2002-07-09 Eli Lilly And Company Methods of inhibiting CNS problems in post-menopausal women
US5596106A (en) * 1994-07-15 1997-01-21 Eli Lilly And Company Cannabinoid receptor antagonists
US5512296A (en) * 1994-08-22 1996-04-30 Eli Lilly And Company Methods for inhibiting neuronal damage
IL120266A (en) * 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
TW442286B (en) * 1996-02-28 2001-06-23 Pfizer New therapeutic uses of estrogen agonists
US6110942A (en) * 1996-06-17 2000-08-29 Eli Lilly And Company Method for minimizing the uterotrophic effect of droloxifene
ZA982877B (en) * 1997-04-09 1999-10-04 Lilly Co Eli Treatment of central nervous system disorders with selective estrogen receptor modulators.
US6117911A (en) 1997-04-11 2000-09-12 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
US6008232A (en) * 1997-08-20 1999-12-28 Eli Lilly And Company Methods for preventing headaches
US6096781A (en) * 1997-11-14 2000-08-01 Eli Lilly And Company 2-arylbenzo[B]thiophenes useful for the treatment of estrogen deprivation syndrome
AU3306399A (en) * 1998-03-02 1999-09-20 Eli Lilly And Company Fluoxetine hydrochloride for decreasing hot flashes
US6288108B1 (en) 1998-06-16 2001-09-11 Eli Lilly And Company Methods for increasing levels of acetylcholine
TR200003704T2 (tr) 1998-06-16 2001-06-21 Eli Lilly And Company Asetilkolin düzeylerini arttırma
US6258826B1 (en) 1998-10-13 2001-07-10 Eli Lilly And Company Pharmaceutical formulations and applications thereof for the treatment of estrogen deprivation syndrome
CN1250563C (zh) 1999-05-04 2006-04-12 斯特拉坎有限公司 雄激素糖苷及其产生雄性征的活性
RU2192639C1 (ru) * 2001-04-05 2002-11-10 Дальневосточный государственный медицинский университет Способ прогнозирования нарушений в постменопаузальном периоде
US6613083B2 (en) 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
KR20050119676A (ko) * 2003-03-31 2005-12-21 제노포트 인코포레이티드 가바 유사체의 프로드러그를 사용한 열성 홍조의 치료 또는예방
EP2323688B1 (en) 2008-07-22 2018-10-17 MenoGeniX, Inc. Compositions and methods for treating symptoms associated with menopause, hormonal variations and arthritis
US9151289B2 (en) 2008-08-21 2015-10-06 Cummins Inc. Fuel pump

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE637389A (no) * 1962-09-13
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4380635A (en) * 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4729999A (en) * 1984-10-12 1988-03-08 Bcm Technologies Antiestrogen therapy for symptoms of estrogen deficiency
US5395842A (en) * 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体
US5391557A (en) * 1993-10-15 1995-02-21 Eli Lilly And Company Methods for the treatment of peri-menopausal syndrome

Also Published As

Publication number Publication date
AU691844B2 (en) 1998-05-28
JPH07196500A (ja) 1995-08-01
HU9403662D0 (en) 1995-02-28
NO944934D0 (no) 1994-12-19
EP0659415A3 (en) 1995-10-11
NO944934L (no) 1995-06-22
NZ270168A (en) 1997-07-27
IL112038A0 (en) 1995-03-15
CN1108093A (zh) 1995-09-13
HUT71478A (en) 1995-11-28
KR950016730A (ko) 1995-07-20
US5534526A (en) 1996-07-09
AU8154894A (en) 1995-06-29
EP0659415A2 (en) 1995-06-28
CZ320994A3 (en) 1995-08-16
ZA9410093B (en) 1996-06-19
CA2138499A1 (en) 1995-06-22
RU94045278A (ru) 1996-11-10

Similar Documents

Publication Publication Date Title
PH31327A (en) Method for inhibiting vasomotor symptoms and attending psychological disturbances surrounding post-menopausal syndrome.
GB9203470D0 (en) Unprocessed petroleum gas transport
EP0655625A3 (en) Sensor elements and processes for their manufacture.
EP0613716A3 (en) Gas transmission device.
EP0671907A4 (en) COMPOSITION AND METHOD FOR INDUCING SATITY.
EP0644374A3 (en) Oxy-fuel burner and method of use.
ZA928975B (en) Method and apparatus for recovering a sterilizing gas.
EP0665281A3 (en) Integrated process for the production of distillates.
PL312566A1 (en) Device for mining high beds
EP0601848A3 (en) System and method for knowledge based design.
EP0684548A4 (en) INTEGER DIVISION DEVICE AND METHOD.
EP0663554A3 (de) Gleitkufenring und Verfahren zu seiner Herstellung.
PH30727A (en) Purification method and apparatus.
ZA921625B (en) Gas separation method and apparatus.
EP0612481A3 (de) Einrichtung zum Transport und zur Bevorratung von Zigaretten.
EP0609495A3 (en) Behavior and device for monitoring the presence of a gas.
EP0611054A3 (en) Derivative apparatus and method for polynomial sets.
EP0667716A4 (en) DEVICE AND METHOD FOR CODING IMAGES.
EP0608492A3 (en) Delta row decompression method and device.
EP0579175A3 (en) Multi-structured protective device made of paper and device for its production.
EP0598393A3 (en) Method and device for removing the outer shell.
ZA928302B (en) Device for ring section furnace.
EP0614154A3 (en) Method and device for improving multi-tone images.
EP0659311A4 (en) EQUALIZATION METHOD AND APPARATUS FOR CONNECTION POINT.
EP0749314A4 (en) PROCESS FOR THE TREATMENT AND INHIBITION OF GASTRIC AND DUODENAL ULCERS